Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr-Jun;38(2):121-7.
doi: 10.1016/j.bjhh.2016.02.003. Epub 2016 Mar 9.

Mature B cell neoplasms: retrospective analysis of 93 cases diagnosed between 2011 and 2014 in a University Hospital in southern Brazil

Chandra Chiappin Cardoso  1 , Ana Carolina Rabello de Moraes  1 , Joanita Angela Gonzaga Del Moral  1 , Maria Claudia Santos-Silva  2
Affiliations

Mature B cell neoplasms: retrospective analysis of 93 cases diagnosed between 2011 and 2014 in a University Hospital in southern Brazil

Chandra Chiappin Cardoso et al. Rev Bras Hematol Hemoter. 2016 Apr-Jun.

Abstract

Background: According to the 2008 World Health Organization classification, mature B-cell neoplasms are a heterogeneous group of diseases that include B-cell lymphomas and plasma cell disorders. These neoplasms can have very different clinical behaviors, from highly aggressive to indolent, and therefore require diverse treatment strategies.

Objective: The aim of this study was to assess the profile of 93 patients diagnosed with mature B-cell neoplasms monitored between 2011 and 2014.

Methods: A review of patients' charts was performed and laboratory results were obtained using the online system of the Universidade Federal de Santa Catarina.

Results: The study included 93 adult patients with mature B-cell neoplasms. The most frequent subtypes were multiple myeloma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and Burkitt's lymphoma. The median age at diagnosis was 58 years with a male-to-female ratio of 1.3:1. There were statistical differences in terms of age at diagnosis, lactate dehydrogenase activity and Ki-67 expression among the subtypes of B-cell lymphoma. According to the prognostic indexes, the majority of multiple myeloma patients were categorized as high risk, while the majority of chronic lymphocytic leukemia patients were classified as low risk.

Conclusions: This study demonstrates the profile of patients diagnosed with mature B-cell neoplasms in a south Brazilian university hospital. Of the B-cell lymphoma, Burkitt's lymphoma presented particular features regarding lactate dehydrogenase activity levels, Ki-67 expression, age at diagnosis, and human immunodeficiency virus infection.

Keywords: Diagnosis; Mature B-cell neoplasms; Prognosis; Treatment response.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prevalence of the mature B-cell neoplasms subgroups. CLL/SLL: chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL: diffuse large B-cell lymphoma; BCL-U: B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt's lymphoma; MGUS: monoclonal gammopathy of undetermined significance; BCL-NOS: B-cell lymphoma, not otherwise specified; LPL/WM: lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
Figure 2
Figure 2
Age at diagnosis of mature B-cell neoplasms. CLL/SLL: chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL: diffuse large B-cell lymphoma; BCL-U: B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt's lymphoma; MGUS: monoclonal gammopathy of undetermined significance; BCL-NOS: B-cell lymphoma, not otherwise specified; LPL/WM: lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
Figure 3
Figure 3
Stratification of patients with (A) multiple myeloma, (B) chronic lymphocytic leukemia/small lymphocytic lymphoma, and (C) diffuse large B-cell lymphoma, follicular lymphoma and Burkitt's lymphoma. DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; BL: Burkitt's lymphoma; ND: not defined because of the absence of the result of β2-microglobulin.
Figure 4
Figure 4
Treatment response assessed as complete/partial remission and relapsed/progressive disease. MM: multiple myeloma; CLL/SLL: chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; BL: Burkitt's lymphoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H. 4th ed. International Agency for Research on Cancer; Lyon, France: 2008. WHO classification of tumours of haematopoietic and lymphoid tissues. 479 pp.
    1. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5(4):251–262. - PubMed
    1. Roman E., Smith A.G. Epidemiology of lymphomas. Histopathology. 2011;58(1):4–14. - PubMed
    1. Ludwig H., Miguel J.S., Dimopoulos M.A., Palumbo A., Garcia Sanz R., Powles R. International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2014;28(5):981–992. - PubMed
    1. Nogai H., Dorken B., Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol. 2011;29(14):1803–1811. - PubMed

LinkOut - more resources